DURING RECENT MONTHS, some labs are reporting improvement in how their claims for certain molecular and genetic tests are being reimbursed. This is progress from the financial crises experienced during 2013 for many labs performing molecular and genetic tests.
Disruption in these payments was one of the clinical lab industry’s biggest stories during 2013. There was a major upheaval in coverage and payment guidelines associated with molecular and genetic tests because both government and private payers were not prepared to deal with the implementation of 114 new CPT codes for specific molecular assays and genetic tests.
Read full article (PDF download)
No part of this article may be reproduced or posted online without permission from THE DARK REPORT. This document contains confidential copyrighted material.